FINWIRES · TerminalLIVE
FINWIRES

SHE:002294

11 stories mentioning SHE:002294Updated 2d ago

Every FINWIRES story that references SHE:002294, newest first.

What's the latest news on SHE:002294?

Asia

China Stocks Rise as PBOC Holds Rates Steady; Salubris Pharmaceuticals Up 3%

Chinese shares closed higher Monday amid signals of a steady monetary policy stance. The gains follow the People's Bank of China's monthly rate fixing on Sunday, where policymakers held the one-year loan prime rate steady at 3% and the five-year LPR at 3.5%.The Shanghai Composite Index, the main gauge of Chinese stocks, rose nearly 1.0% to close at 3,949.91. The Shenzhen Component Index climbed 0.7% to 13,730.02.On the regulatory front, China will tighten rules around price competition to prevent malicious price competition and predatory pricing. As part of the country's 15th Five-Year Plan, the State Administration for Market Regulation will accelerate revisions to the Price Law to establish a legal framework penalizing below-cost dumping.Authorities will also fully implement the revised Anti-Unfair Competition Law to crack down on market malpractices, including false advertising, commercial discrediting, and bribery.In company news, Shenzhen Salubris Pharmaceuticals (SHE:002294) will repurchase a combined 6.14% stake in controlled subsidiary Sino Medical from two strategic investors for about 426.7 million yuan, raising its stake to 93.51% from 87.36%. Shares of the pharmaceutical company closed 3% higher Monday.

Shanghai Composite^SZSESHE:002294
Asia

Salubris Pharmaceuticals to Raise Stake in Sino Medical Unit to 93.51%; Shares Up 3%

Shenzhen Salubris Pharmaceuticals (SHE:002294) will repurchase a combined 6.14% stake in controlled subsidiary Sino Medical from two strategic investors for about 426.7 million yuan.Upon completion, the pharmaceutical company's stake in Sino Medical will rise to 93.51% from 87.36%, according to a weekend filing with the Shenzhen bourse.Shares of Salubris Pharmaceuticals rose 3% in recent trade.

SHE:002294
Asia

Salubris Pharmaceuticals Resubmits Hong Kong Listing Application

Shenzhen Salubris Pharmaceuticals (SHE:002294) submitted an updated application for the offering and listing on the Hong Kong Stock Exchange, according to a Friday disclosure on the Shenzhen bourse.The pharmaceutical company submitted its first Hong Kong listing application in February.

SHE:002294
Asia

Shenzhen Salubris Pharmaceuticals Gets Nod for Solid Tumor Treatment Trial

Shenzhen Salubris Pharmaceuticals (SHE:002294) has received approval from China's National Medical Products Administration for the clinical trial of its SAL012 injection.The drug will be tested as a treatment for advanced solid tumors, according to a Shenzhen bourse filing on Saturday.

SHE:002294
Asia

Salubris Pharma Gets Nod for SAL0195 Injection Trial

Shenzhen Salubris Pharmaceuticals (SHE:002294) received approval from China's National Medical Products Administration for the clinical trial of its SAL0195 injection.The drug will be tested as a treatment for elevated lipoprotein(a) levels, according to a Shenzhen bourse filing on Saturday.

SHE:002294
Asia

Shenzhen Salubris Pharmaceuticals Receives China Approval for Hypercholesterolemia Drug Clinical Trial; Shares Slide 4%

Shenzhen Salubris Pharmaceuticals (SHE:002294) received approval from China's National Medical Products Administration to conduct a clinical trial for its self-developed SAL0167 tablets, according to a Thursday filing with the Shenzhen Stock Exchange.The drug targets hypercholesterolemia or high cholesterol levels.Shares fell nearly 4% in recent trade.

SHE:002294
Asia

Salubris Pharmaceuticals Unit Presents JK06's Clinical Trial Results At American Oncology Convention

Shenzhen Salubris Pharmaceuticals' (SHE:002294) unit, Salubris Biotherapeutics, presented the results of its clinical trial on the drug JK06 at the American Society of Clinical Oncology Annual Meeting, according to a Shenzhen bourse filing on Wednesday.The trials showed that the drug has safety and efficacy in patients with tumors, including non-small cell lung cancer and breast cancer.The trial enrolled 173 patients in Europe.Shares of the pharmaceutical company were down 2% at the close.

SHE:002294
Asia

Salubris Pharma's Clinical Trial Application for Lipid-Lowering Drug Accepted in China

Shenzhen Salubris Pharmaceuticals (SHE:002294) said China's drug regulator accepted its clinical trial application for SAL0195.The drug targets lipid-related diseases, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 2% in recent trade.

SHE:002294
Asia

Salubris Subsidiary Gets China Nod for Osteoporosis Injection

China's drug regulator approved Shenzhen Salubris Pharmaceuticals' (SHE:002294) subsidiary Salubris (Suzhou) Pharmaceutical's drug registration for its recombinant teriparatide for injection.The drug, a subcutaneous powder injection taken once weekly, helps treat osteoporosis in post-menopausal women with a high risk of fractures, according to a Saturday filing with the Shenzhen bourse.

SHE:002294
Asia

Salubris Pharma's 2025 Profit Rises 8%, Revenue Climbs 9%; Shares Down 3%

Shenzhen Salubris Pharmaceuticals' (SHE:002294) net profit attributable to shareholders in 2025 rose 8.3% to 651.5 million yuan from 601.6 million yuan a year earlier, according to a Shenzhen bourse filing on Tuesday.Earnings per share climbed 7.4% year on year to 0.58 yuan from 0.54 yuan.Operating revenue increased 8.5% to 4.35 billion yuan from 4.01 billion yuan in the prior year.The pharmaceutical company's shares fell by over 3% during the midday trade.

SHE:002294
Asia

Salubris Pharmaceuticals' Subsidiary Presents Positive Effects of JK06 At American Association for Cancer Research

Shenzhen Salubris Pharmaceuticals' (SHE:002294) subsidiary, Salubris Biotherapeutics, presented the positive effects of the JK06 at the American Association for Cancer Research, according to a Shenzhen bourse filing on Monday.The drug was tested for metastatic tumors, including non-small cell lung cancer and breast cancer, in phases 1/2 clinical trials.The drug showed good safety and efficacy in patients during the trials.The pharmaceutical company's shares dropped 4% during the afternoon trade.

SHE:002294

Track with the FINWIRES app suite